Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by RMR Wealth Builders

RMR Wealth Builders increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 14.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,835 shares of the pharmaceutical company’s stock after purchasing an additional 596 shares during the period. RMR Wealth Builders’ holdings in Vertex Pharmaceuticals were worth $2,344,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. ABC Arbitrage SA acquired a new stake in Vertex Pharmaceuticals during the 4th quarter worth $1,510,000. Highview Capital Management LLC DE boosted its stake in Vertex Pharmaceuticals by 1.8% during the 4th quarter. Highview Capital Management LLC DE now owns 5,771 shares of the pharmaceutical company’s stock worth $2,324,000 after purchasing an additional 102 shares during the period. Davidson Investment Advisors boosted its stake in Vertex Pharmaceuticals by 26.0% during the 4th quarter. Davidson Investment Advisors now owns 61,161 shares of the pharmaceutical company’s stock worth $24,630,000 after purchasing an additional 12,631 shares during the period. Jones Financial Companies Lllp boosted its stake in Vertex Pharmaceuticals by 75.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,468 shares of the pharmaceutical company’s stock worth $994,000 after purchasing an additional 1,062 shares during the period. Finally, New York State Common Retirement Fund boosted its stake in Vertex Pharmaceuticals by 0.8% during the 4th quarter. New York State Common Retirement Fund now owns 362,334 shares of the pharmaceutical company’s stock worth $145,912,000 after purchasing an additional 2,855 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

VRTX stock opened at $460.06 on Friday. The firm has a 50 day moving average of $462.88 and a 200-day moving average of $460.24. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The company has a market cap of $118.14 billion, a price-to-earnings ratio of -209.12, a PEG ratio of 2.11 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. During the same quarter in the previous year, the business posted $4.76 earnings per share. Vertex Pharmaceuticals’s revenue was up 2.6% on a year-over-year basis. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Cantor Fitzgerald restated an “overweight” rating and set a $535.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Wall Street Zen upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, March 11th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Vertex Pharmaceuticals from $512.00 to $515.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 6th. Fourteen equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $515.04.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.